ArticleJournal of clinical pharmacology2020

Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure-Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib.

Mohamed-Eslam F Mohamed et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.